^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

VHL deletion

i
Other names: VHL, von Hippel-Lindau tumor suppressor, RCA1, VHL1, pVHL, HRCA1
Entrez ID:
Related biomarkers:
2ms
HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells. (PubMed, Nat Commun)
Restoration of intracellular acetyl-CoA by acetate supplementation re-engages AICD, rescuing IFN-γ production in hypoxic Hif1α-/- T cells and re-sensitizing Hif1α-/- tumor-bearing mice to ICB. In summary, we identify HIF1α-regulated glycolysis as a key metabolic control of IFN-γ production in hypoxic T cells and ICB response.
Journal
|
IFNG (Interferon, gamma) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
VHL deletion
over1year
Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma. (PubMed, Signal Transduct Target Ther)
Genetic deletion or antibody blockade of POSTN dramatically suppressed lung metastases in our preclinical models. This work supports a new strategy to halt the progression of ccRCC by disrupting the critical metastatic crosstalk between heterogeneous cell populations within a tumor.
Journal
|
VHL (von Hippel-Lindau tumor suppressor)
|
VHL deletion
over1year
Genotype-phenotype correlations and clinical outcomes of von Hippel-Lindau disease patients with large deletions (AUA 2023)
The number of generations and the status of exon 2 could affect onset age of VHL-related manifestation. Onset age was an independent risk factor for overall survival. TKIs therapy was effective for VHL patients with LDs.
Clinical • Clinical data
|
CHEK2 (Checkpoint kinase 2) • FLCN (Folliculin)
|
VHL deletion
2years
Identifying metastatic renal cell carcinoma in thyroid fine needle aspirates by molecular testing. (PubMed, Endocr Relat Cancer)
Of the 14 patients with medical history or surgical follow-up available, all had the history of RCC or renal mass or revealed metastatic RCC on thyroidectomy. This study demonstrates that molecular testing can reliably identify metastatic RCC in thyroid nodules with indeterminate cytology, which could improve patient management.
Journal
|
VHL (von Hippel-Lindau tumor suppressor)
|
VHL mutation • VHL deletion
2years
PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma. (PubMed, Nat Rev Urol)
These three proteins have multiple roles in the regulation of crucial cancer-related pathways, including protection of genomic stability, antagonism of polycomb group (PcG) complexes to maintain a permissive transcriptional landscape in physiological conditions, and regulation of genes that mediate responses to immune checkpoint inhibitor therapy. An improved understanding of these mechanisms will bring new insights regarding cellular drivers of ccRCC growth and therapy response and, ultimately, will support the development of novel translational therapeutics.
Review • Journal
|
BRCA1 (Breast cancer 1, early onset) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)
|
VHL deletion
2years
Mutation of the proline P81 into a serine modifies the tumour suppressor function of the von Hippel-Lindau gene in the ccRCC. (PubMed, Br J Cancer)
We demonstrated the pathogenic role of this mutation in tumour development in vhl patients and confirm a medical follow up of family carrying the c.241C>T, P81S.
Journal
|
VHL (von Hippel-Lindau tumor suppressor)
|
VHL mutation • VHL deletion
over2years
Polybromo-1 missense mutations found in renal cancer patients affect bromodomain stability and biological function. (PubMed, FASEB J)
Using recombinant PBRM1 BD4 mutants, we have assessed how the most common missense mutations found in patients affect the stability and acetyllysine binding of PBRM1 BD4, revealing new insight into bromodomain structure and function. In addition we have expressed a subset of these PBRM1 missense mutations in renal cancer cell lines and assessed how they affect PBRM1 binding to acetyllysine substrates, and subsequent renal cancer growth.
Journal
|
PBRM1 (Polybromo 1)
|
PBRM1 mutation • VHL mutation • PBRM1 deletion • VHL deletion
almost3years
Negative cellular outcomes following acute in vivo Vhl inactivation in mice (AACR 2022)
One week after inactivation was induced by administration of tamoxifen, there were equal numbers of tdTomato-positive cells in both genotypes, implying that initial recombination was similar and that Vhl KO did not affect immediate cell survival...Currently we are investigating the role of these additional perturbations in modifying the cellular response to Vhl loss. Our study will provide new insights into the genesis of ccRCC by redefining the mechanisms underlying the creation of pro-tumorigenic niches following Vhl inactivation.
Preclinical
|
PBRM1 (Polybromo 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • VHL (von Hippel-Lindau tumor suppressor) • HMGB1 (High Mobility Group Box 1)
|
PBRM1 mutation • HIF1A expression • VHL deletion
|
tamoxifen
almost3years
PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma. (PubMed, Acta Pharmacol Sin)
Rapalogs (everolimus and temsirolimus) are allosteric mTORC1 inhibitors and approved agents for advanced clear cell renal cell carcinoma (ccRCC), although only a subset of patients derive clinical benefit. Of note, PTEN protein loss as detected by immunohistochemistry is much more frequent than mutations in the PTEN gene in ccRCC patients. Our study suggests that PTEN loss correlates with rapalog sensitivity and could be used as a marker for ccRCC patient selection for rapalog therapy.
Journal
|
PTEN (Phosphatase and tensin homolog) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • KDM5C (Lysine Demethylase 5C)
|
MTOR A2034V • VHL deletion
|
everolimus • Torisel (temsirolimus)
3years
Clear cell and papillary renal cell carcinomas in hereditary papillary renal cell carcinoma (HPRCC) syndrome: a case report. (PubMed, Diagn Pathol)
The pathologist must be aware that the presence of a non-papillary RCC associated with numerous papillary tumors should not exclude the diagnostic suspicion of HPRCC and thus to perform a thorough genomic study.
Clinical • Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • VHL (von Hippel-Lindau tumor suppressor) • CA9 (Carbonic anhydrase 9)
|
VHL mutation • MET mutation • CA9 expression • VHL deletion
3years
Hypoxia inducible factor signaling in breast tumors controls spontaneous tumor dissemination in a site-specific manner. (PubMed, Commun Biol)
Mice with Hif1α deleted tumors also exhibit reduced bone volume as measured by micro computed tomography, suggesting that disruption of the osteogenic niche may be involved in the preference for lung dissemination observed in this group. Thus, we reveal that HIF signaling in breast tumors controls tumor dissemination in a site-specific manner.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • EPAS1 (Endothelial PAS domain protein 1)
|
VHL deletion
almost4years
Comprehensive characterization of Alu-mediated breakpoints in germline VHL gene deletions and rearrangements in patients from 71 VHL families. (PubMed, Hum Mutat)
Ninety-five percent (55 of 58) of mapped deletions involve Alu repeats at both breakpoints. Several novel classes of deletions were identified in this cohort, including two cases that have complex rearrangements involving both deletion and inversion, two cases with inserted extra Alu-like sequences, six cases that involve breakpoints in Alu repeats situated in opposite orientations, and a "hotspot" PD of exon 3 observed in 12 families that involves the same pair of Alu repeats.
Clinical • Journal
|
VHL (von Hippel-Lindau tumor suppressor)
|
VHL deletion
over4years
Von Hippel-Lindau syndrome and renal tumours: radiological diagnostic and treatment options. A case report and literature review. (PubMed, Acta Med Litu)
After that, for past 11 years multiple renal tumours were removed by cryoablation and patient monitoring on contrast-enhanced magnetic resonance (MRI) and CECT control scans was conducted. Active multidisciplinary patient follow-up, routine radiological examinations, and correct treatment tactics allow controlling the  progression of renal cell carcinoma and other tumours associated with VHL syndrome, maintaining a normal organ function for a long time, and preventing distant metastases and fatal disease outcomes.
Clinical • Journal
|
VHL (von Hippel-Lindau tumor suppressor)
|
VHL deletion
over4years
[VIRTUAL] Develop dual-targeted CAR-T cells to achieve RCC cures (AACR-II 2020)
Dual-targeted anti-CAIX/CD70 CD4/8 CAR-T cells outperformed singly-targeted CAR-T cells with elevated efficacy. In summary, anti-CAIX/CD70 CAR-T cells hold a great promise to achieve ccRCC cures.
CAR T-Cell Therapy • IO biomarker
|
CD8 (cluster of differentiation 8) • VHL (von Hippel-Lindau tumor suppressor) • CD70 (CD70 Molecule) • CA9 (Carbonic anhydrase 9)
|
HIF1A expression • VHL deletion